why choose us

First received: June 15, 2023

Clinical Trial: Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

Study Status: Completed

Recruit Status: RECRUITING

Condition: Acute Coronary Syndrome

Study Type: INTERVENTIONAL


Official Title: Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrom

Brief Summary: This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile.Subjects will provide informed consent before any study-specific procedures are performed.A separate informed consent will be allowed for an initial pre-screening genetic testing.Subjects meeting the AA genotype will then consent to the full study and confirmatory genetic testing as required.Subject enrollment may begin in the hospital…

Read more